Japanese CMO Fujifilm Diosynth spends extra $28M in US, UK mAb facilities
Fujifilm Diosynth Biotechnologies is channeling another $28 million from its parents company into two new manufacturing facilities in Texas and the UK, aggressively adding equipment and space to $123 million worth of machines and buildings that were just announced in April.
A relative newcomer to the contract development and manufacturing business, the subsidiary of Japanese Fujifilm Corp is keen on gaining market share from the likes of Lonza and Catalent. The two sites being expanded specialize in monoclonal antibodies; due to high demand, the company says they decided to pour in extra money earlier than scheduled, even before the facilities are fully operational.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.